This TRAN1 award helped to fund the development of Siren Biotechnology’s lead therapy, SRN-101, for high-grade glioma brain cancers in patients. In this reporting period, we completed the final Operational Milestone of our TRAN1 award. This Operational Milestone included the preparation for and completion of our pre-Investigational New Drug (pre-IND) meeting with the FDA, wherein we received feedback on our current data and upcoming clinical trial plans. Completion of this Operational Milestone represents a culmination of ~16 months of development work for SRN-101 in California that encompassed nonclinical animal studies and optimization of our manufacturing process for our clinical drug product. Work completed under this TRAN1 award was overwhelmingly productive and successful, and allows us to advance SRN-101 toward the clinic in 2026 with confidence. Siren Biotechnology looks forward to continuing to work with CIRM to advance SRN-101 for patients in California and beyond.